Toposar

• Antineoplastic Agents, Phytogenic
• Nucleic Acid Synthesis Inhibitors
• ATC:L01CB01

• (-)-Etoposide
• Eposin
• Etopophos
• Etopophos Preservative Free
• Etoposide (JAN/USP)
• Etoposide USP26
• Etoposidum [INN-Latin]
• Lastet
• Teniposide
• Toposar
• VePESID (TN)
• Vepesid
• Vepesid J
• Zuyeyidal
• trans-Etoposide

• No information avaliable

C₂₉H₃₂O₁₃

http://www.rxlist.com/cgi/generic2/etopophos.htm

http://www.accessdata.fda.gov/scripts/cder/onctools/labels.cfm?GN=etoposide,%20VP-16

Toposar MSDS

No information avaliable

588.557 g/mol

236-251 ^oC

58.7 mg/L

Solid

1.197

Solution; Capsule; Liquid

For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Etoposide is an antineoplastic agent and an epipodophyllotoxin (a semisynthetic derivative of the podophyllotoxins). It inhibits DNA topoisomerase II, thereby inhibiting DNA synthesis. Etoposide is cell cycle dependent and phase specific, affecting mainly the S and G2 phases. Two different dose-dependent responses are seen. At high concentrations (10 µg/mL or more), lysis of cells entering mitosis is observed. At low concentrations (0.3 to 10 µg/mL), cells are inhibited from entering prophase. It does not interfere with microtubular assembly. The predominant macromolecular effect of etoposide appears to be the induction of DNA strand breaks by an interaction with DNA-topoisomerase II or the formation of free radicals.

Absorbed well, time to peak plasma concentration is 1-1.5 hrs. Mean bioavailability is 50%.

Side effects include alopecia, constipation, diarrhea, nausea and vomiting and secondary malignancies (leukemia).

Patients are generally advised to call their doctor in case of fever, symptoms of infection or painful injection sites, as these may progress severely without adequate medical attention. It is advised to drink lots of fluids after treatment to prevent damage to the bladder and kidneys, typically 1.5 to 3.5 litres of water on the day of treatment and for several days after.

Humans and other mammals